Timothy Sullivan - Sep 8, 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/ David Watson, attorney-in-fact for Timothy Sullivan
Stock symbol
APLS
Transactions as of
Sep 8, 2025
Transactions value $
-$1,039,680
Form type
4
Date filed
9/10/2025, 04:02 PM
Previous filing
Jun 11, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sullivan Timothy Eugene Chief Financial Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Timothy Sullivan 2025-09-10 0001707000

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $150K +15K +11.66% $10.03 144K Sep 8, 2025 Direct F1
transaction APLS Common Stock Sale -$912K -32.7K -22.78% $27.86 111K Sep 8, 2025 Direct F1
transaction APLS Common Stock Sale -$278K -10K -14.21% $27.83 60.4K Sep 8, 2025 The Timothy E Sullivan Irrevocable Trust of 2023 F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -15K -5.82% $0.00 243K Sep 8, 2025 Common Stock 15K $10.03 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is a scheduled exercise & sale from 10b5-1 trading plan dated June 9, 2025.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.98, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
F3 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F4 This option was granted on October 18, 2017 and fully vested.